Patents by Inventor Hualiang Jiang

Hualiang Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210040066
    Abstract: Disclosed are a novel tetrahydroisoquinoline compound, a method for preparing intermediates thereof, a pharmaceutical composition thereof and the use thereof. The tetrahydroisoquinoline compound of the present invention has a good inhibitory effect on phosphodiesterase (PDE4), and can be used in the prevention, treatment or auxiliary treatment of multiple diseases associated with the activity or expression of phosphodiesterase, especially PDE4-associated immune and inflammatory diseases, such as psoriasis and arthritis.
    Type: Application
    Filed: February 3, 2019
    Publication date: February 11, 2021
    Inventors: Yechun XU, Hong LIU, Wei TANG, Xianglei ZHANG, Zhanni GU, Heng LI, Xu HAN, Fenghua ZHU, Chunlan FENG, Guangyu DONG, Tiantian CHEN, Wuyan CHEN, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20200385418
    Abstract: An antidepressant steroid compound and a preparation method and an application thereof; the structure of said compound is shown in formula (I), and the definition of each substituent is as described in the description and claims. Compound of the present invention may be used in the prevention, treatment, therapy or alleviation of a plurality of diseases and conditions such as depression.
    Type: Application
    Filed: December 29, 2017
    Publication date: December 10, 2020
    Inventors: Chenggang HUANG, Yang LI, Hualiang JIANG, Yang XIE, Fei GUO, Zhixiong LI, Mingcang CHEN, Mingyue ZHENG, Zhaolin SUN, Yu GAO, Xiaoting TIAN, Pei HU, Bing ZHANG
  • Publication number: 20200354371
    Abstract: The present invention relates to a bromodomain inhibitor. Provided are a compound represented by general formula I or a pharmaceutically acceptable salt, enantiomer, diastereomer, atropisomer, racemate, polymorph, solvate, or isotopically labeled compound (including deuterium substitution) thereof, a preparation method of the same, a pharmaceutical composition comprising the same, and a pharmaceutical use thereof.
    Type: Application
    Filed: January 11, 2019
    Publication date: November 12, 2020
    Inventors: Bing ZHOU, Cheng LUO, Zizhou LI, Yaxi YANG, Shijie CHEN, Hong DING, Hualiang JIANG, Gang QIAO, Xinjun WANG, Senhao XIAO
  • Patent number: 10800776
    Abstract: A fluorine-containing triazolopyridine represented by formula (I) and a racemate, R-stereoisomer, S-stereoisomer, pharmaceutically acceptable salt, or mixture thereof are described. The triazolopyridine can be used as a positive allosteric modulator of an mGluR2, and is highly selective in activating the mGluR2, exerting no activation or very limited activation of other homologous metabotropic glutamate receptor. The triazolopyridine can thus be used to prepare a product for treating an mGluR2-related disease, such as a central nervous system disease or neurological disease.
    Type: Grant
    Filed: May 17, 2017
    Date of Patent: October 13, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Yu Zhou, Wenjing Xia, Dong Zhang, Hualiang Jiang, Kaixian Chen
  • Publication number: 20200261459
    Abstract: The present invention provides a compound represented by formula I, pharmaceutically acceptable salts, enantiomers, diastereomers or racemates thereof, the preparation method thereof, the pharmaceutical composition comprising the same, and the use thereof in the preparation of a medicament for treating a disease or condition mediated by EED and/or PRC2. The compound of the present invention can be used treating PRC2-mediated diseases or conditions.
    Type: Application
    Filed: August 29, 2018
    Publication date: August 20, 2020
    Inventors: Bing ZHOU, Cheng LUO, Yaxi YANG, Yuanyuan ZHANG, Daohai DU, Hualiang JIANG, Gang QIAO, Xinjun WANG
  • Publication number: 20200255421
    Abstract: The present invention provides a tetrahydroprotoberberine compound represented by the formula (I), enantiomers, diastereomers, racemates and mixtures thereof, and pharmaceutically acceptable salts, crystalline hydrates and solvates thereof. The invention also provides a method for preparing the compound and the use thereof in the preparation of a medicament for preventing and/or treating central nervous system diseases.
    Type: Application
    Filed: August 14, 2018
    Publication date: August 13, 2020
    Inventors: Yang HE, Xiangrui JIANG, Jianfeng LI, Yu WANG, Zhen WANG, Weiming CHEN, Fuqiang ZHU, Chunhui WU, Rongxia ZHANG, Jingshan SHEN, Hualiang JIANG
  • Publication number: 20200190066
    Abstract: It is related to compounds used as autophagy modulators and a method for preparing and using the same, specifically providing a compound of general formula (I), or pharmaceutically acceptable salts thereof, which is a type of autophagy modulators, particularly mammalian ATG8 homologues modulators.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 18, 2020
    Inventors: Cheng LUO, Yuli XIE, Bing ZHOU, Zhiyi YAO, Liyan YUE, Wei WAN, Bidong ZHANG, Yuanyuan ZHANG, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20200170966
    Abstract: The present invention relates to use of an aminomethylenecyclohexane-1,3-dione compound, more particularly to use of a compound shown in the following formula (I) or a pharmaceutically acceptable salt thereof alone or in combination with other drug in preparing a drug for regulating or treating a disease related to autophagy, especially mammalian ATG8 homologous proteins.
    Type: Application
    Filed: May 18, 2018
    Publication date: June 4, 2020
    Inventors: Cheng LUO, Liyan YUE, Wei WAN, Yuanyuan ZHANG, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20200163983
    Abstract: Provided are use of a saponin compound of formula (I) or (II), or a pharmaceutically acceptable salt, prodrug or solvate thereof, in the manufacture of a medicament targeting PD-1. The medicament targeting PD-1 is one which treats a disease by inhibiting PD-1 from binding to a ligand thereof. The disease may be a tumor, an infection caused by a bacterium, a virus or a fungus, or an inflammatory disease.
    Type: Application
    Filed: July 12, 2018
    Publication date: May 28, 2020
    Inventors: Honglin LI, Weilie XIAO, Lili ZHU, Lina QUAN, Qiao LI, Yanyan DIAO, Zhenjiang ZHAO, Hualiang JIANG
  • Publication number: 20200140415
    Abstract: The present disclosure relates to a salt of phenyl pyrimidinone compound, a polymorph thereof and a pharmaceutical composition comprising the same and a use thereof, particularly relates to the hydrochlorate of phenyl pyrimidinone compound of following formula (I-A) and a pharmaceutically acceptable polymorph, solvate, hydrate, co-crystal, anhydrous substance, or amorphous form thereof, a pharmaceutical composition and a pharmaceutical unit dosage comprising the same, the preparing method and use thereof.
    Type: Application
    Filed: January 7, 2020
    Publication date: May 7, 2020
    Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANGHAI CO., LTD.
    Inventors: Jingshan Shen, Yang He, Weiming Chen, Jianfeng Li, Guanghui Tian, Xudong Gong, Zhen Wang, Rongxia Zhang, Yongjian Liu, Hualiang Jiang
  • Patent number: 10618900
    Abstract: Compounds of formula I are provided. Also provided are methods of preparing the compounds of formula (I), and methods of using the compounds of formula (I) as a negative allosteric modulator of a metabotropic glutamate receptor (mGluR) subtype 5.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 14, 2020
    Assignee: Shanghai Institute of Materia Medica, Chinese Academy of Sciences
    Inventors: Hong Liu, Yu Zhou, Dong Zhang, Jian Li, Hualiang Jiang, Kaixian Chen
  • Publication number: 20200071291
    Abstract: The present invention provides an isoindolone-imide ring-1,3-dione-2-ene compound, and a preparation method, a pharmaceutical composition and use thereof. Specifically, the present invention provides a compound of Formula (I) below or a pharmaceutically acceptable salt thereof, wherein Ar is an isoindolinone-imide group represented by Formula (II), L is absent or is a divalent, trivalent or tetravalent linking group, and X is a group represented by Formula (III). Definitions of the other groups are as described in the specification. The compound of Formula (I) is an autophagy modulators, particularly a mammalian ATG8 homolog modulator.
    Type: Application
    Filed: May 17, 2018
    Publication date: March 5, 2020
    Inventors: Zhiyi YAO, Cheng LUO, Yuli XIE, Liyan YUE, Wei WAN, Yuanyuan ZHANG, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20200069609
    Abstract: The present invention provides a method (I) for modifying a mammalian ATG8 homologue by a covalent bond, comprising: providing a compound SM-LG including a moiety SM- having a function of modulating a mammalian ATG8 homologue and a leaving moiety -LG; the compound SM-LG reacts with a mammalian ATG8 homologue to produce a covalent complex of the mammalian ATG8 homologue. The invention also provides a covalent complex of the mammalian ATG8 homologue obtained by the method and uses of the same.
    Type: Application
    Filed: May 18, 2018
    Publication date: March 5, 2020
    Inventors: Cheng LUO, Zhiyi YAO, Yuli XIE, Wei WAN, Liyan YUE, Yuanyuan ZHANG, Hualiang JIANG, Kaixian CHEN
  • Patent number: 10479798
    Abstract: The present invention relates to six-membered ring benzo derivatives as a DPP-4 inhibitor and a use thereof. In particular, the present invention relates to a compound as shown in formula I, a pharmaceutical composition containing the compound as shown in formula I and a use of the compound in the preparation of drugs for treating DPP-4 related diseases or inhibiting DPP-4.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: November 19, 2019
    Assignees: EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Honglin Li, Hualiang Jiang, Yufang Xu, Jia Li, Zhenjiang Zhao, Jingya Li, Hongling Xu, Shiliang Li
  • Publication number: 20190202827
    Abstract: A fluorine-containing triazolopyridine represented by formula (I) and a racemate, R-stereoisomer, S-stereoisomer, pharmaceutically acceptable salt, or mixture thereof are described. The triazolopyridine can be used as a positive allosteric modulator of an mGluR2, and is highly selective in activating the mGluR2, exerting no activation or very limited activation of other homologous metabotropic glutamate receptor. The triazolopyridine can thus be used to prepare a product for treating an mGluR2-related disease, such as a central nervous system disease or neurological disease.
    Type: Application
    Filed: May 17, 2017
    Publication date: July 4, 2019
    Inventors: Hong LIU, Yu ZHOU, Wenjing XIA, Dong ZHANG, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20190135818
    Abstract: The present invention provides a compound comprising a 5-membered heterocycle fused with a pyridazinone, wherein the compound is used as an FGFR kinase inhibitor, and a manufacturing method and application thereof. The invention specifically provides a compound as represented by formula (I). Various radicals are as defined in the specification. The compound provided by the invention effectively inhibits an activity of an FGFR kinase, and can be used to manufacture a pharmaceutical product for treating a disease related to the activity of the FGFR kinase.
    Type: Application
    Filed: May 24, 2017
    Publication date: May 9, 2019
    Inventors: Hualiang JIANG, Hong LIU, Meiyu GENG, Mingyue ZHENG, Jing AI, Yulan WANG, Xiaowei WU, Shuangjie LI, Xia PENG, Chunpu LI, Kaixian CHEN, Bao WANG
  • Publication number: 20190100529
    Abstract: The invention describes a polymorph of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid maleate and a preparation method therefor. The polymorph is a crystal having high stability and low hygroscopicity, and the crystal form is selected from crystal form A, crystal form B and crystal form C. Furthermore, the crystal form has a strong in-vivo hypoglycemic activity and can be used for the preparation of a novel drug for the treatment or prevention of diabetes mellitus type H and/or complications of diabetes mellitus type H.
    Type: Application
    Filed: March 20, 2017
    Publication date: April 4, 2019
    Inventors: Hong LIU, Jiang WANG, Jian LI, Jia LI, Jingya LI, Hualiang JIANG, Xiaomin LUO, Kaixian CHEN
  • Publication number: 20190100507
    Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.
    Type: Application
    Filed: March 16, 2017
    Publication date: April 4, 2019
    Inventors: Hong LIU, Jia LI, Jiang WANG, Mingbo SU, Shuni WANG, Yubo ZHOU, Wei ZHU, Wei XU, Chunpu LI, Hualiang JIANG, Kaixian CHEN
  • Publication number: 20190031678
    Abstract: The invention relates to a salt form of (R)-methyl-2-(3-aminopiperidin-1-yl)-3-(2-cyanobenzyl)-4-carbonyl-3,4-dihydrothiophene[3,2-d]pyrimidine-6-carboxylic acid and a preparation method for the salt form. Also disclosed is a pharmaceutical composition of the formula I compound salt form.
    Type: Application
    Filed: March 22, 2017
    Publication date: January 31, 2019
    Applicants: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES
    Inventors: Hong LIU, Jiang WANG, Jian LI, Jia LI, Jingya LI, Hualiang JIANG, Xiaomin LUO, Kaixian CHEN
  • Patent number: 10174011
    Abstract: The present invention provides a heterocyclic compound represented by the formula (I), its stereoisomers, or a pharmaceutically acceptable salt thereof, pharmaceutical compositions thereof, and their use in preparing a medicament for the prevention and/or treatment of central nervous system disease.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: January 8, 2019
    Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SUZHOU VIGONVITA LIFE SCIENCES CO., LTD., TOPHARMAN SHANDONG CO., LTD.
    Inventors: Hualiang Jiang, Zhen Wang, Jianfeng Li, Rongxia Zhang, Yang He, Yongjian Liu, Minghao Bi, Zheng Liu, Guanghui Tian, Weiming Chen, Feipu Yang, Chunhui Wu, Yu Wang, Xiangrui Jiang, Jingjing Yin, Guan Wang, Jingshan Shen